Oxford’s Sarah Gilbert Outlines Coronavirus Vaccine Plans

Hopes COVID-19 Jab And Manufacturing Capacity Ready By September

Oxford University vaccines expert Sarah Gilbert says the first UK vaccine candidate to prevent the SARS-CoV-2 coronavirus will begin clinical testing in healthy volunteers next week and that “prospects are very good” an effective COVID19 jab could be available by September.

Covid-19
“We need to make vaccine for the world.” - Sarah Gilbert • Source: Shutterstock

Sarah Gilbert, who is a professor of vaccinology at the University of Oxford in the UK and a leading scientist at the university’s Jenner Institute, has outlined to the media her team’s plans to advance a vaccine using recombinant DNA techniques to create a SARS-CoV-2 antigen and embedding it within a primate adenovirus vector. She expressed the hope and aim of having a viable anti-COVID-19 product “available for global use” by September.

Gilbert’s team of experts was awarded a £2.2m grant from the UK’s National Institute for Health Research and the UK...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Clinical Trials

  • Sciwind Eyes Differentiation For Ecnoglutide In Highly Competitive Arena

     
    • By 

    Chinese firm Sciwind has revealed additional Phase III findings for its promising once-weekly GLP-1 agonist ecnoglutide, just one asset in a burgeoning Chinese sector that could see the emergence of new rivals to current global leaders in obesity and diabetes.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

     
    • By 

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

  • Sponsored By:

    Nancy Tests SPARC-931-part

    The article discusses the impact of upcoming patent expirations in oncology biologics on biosimilar developers, highlighting the opportunities in Antibody-Drug Conjugates (ADCs) and Bispecific Antibodies (BsAbs). It explores the challenges posed by the structural complexities of these biologics, necessitating new bioanalytical tools and manufacturing processes. The evolving regulatory landscape, with contributions from EMA, FDA, and WHO, offers flexible pathways but also presents challenges. The article underscores the potential for biosimilars to generate significant cost savings and enhance patient access to cancer treatments over the next decade.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

More from R&D